We are dedicated to providing resources to patients, practicing clinicians, and all individuals concerned w/ improving the care of patients with kidney disease.
Insight of the Week - Kidney care is evolving—new IgA nephropathy targets, advanced diagnostics like mNGS, and precision medicine are driving earlier detection & tailored treatments for better outcomes. Support research & advocate for kidney health. #Nephrology#Innovation
CHANCE-2 trial: In stroke pts w/ CYP2C19 LOF, ticagrelor cut stroke risk in both age groups w/ normal kidneys, but no benefit in mild impairment. #Stroke#Nephrologyow.ly/92P750WCfCu
Multi-institutional study in pediatric lupus shows reliable capture of BP, proteinuria & RAAS inhibitor use across 6 sites. Findings reveal high hypertension/proteinuria rates, variation in treatment, & opportunities to standardize care. #PediatricLupuspubmed.ncbi.nlm.nih.gov/4039…
💊 Breakthrough in Lupus Nephritis Treatment!
Results from the REGENCY phase 3 trial show that adding obinutuzumab to standard therapy significantly improved kidney outcomes in adults with active lupus nephritis. ow.ly/qE0750YTeA7
🧪 Promising Results in IgA Nephropathy!
A phase 3 trial shows that atrasentan, a selective endothelin A receptor antagonist, significantly reduced proteinuria in patients with IgA nephropathy and high kidney risk.
#KidneyResearch 🔗 Learn more: pubmed.ncbi.nlm.nih.gov/3946…
Breakthrough in Lupus Nephritis Treatment! Results from the REGENCY phase 3 trial show that adding obinutuzumab to standard therapy significantly improved kidney outcomes in adults with active lupus nephritis. Read more: pubmed.ncbi.nlm.nih.gov/3992…#LupusNephritis#ClinicalTrials
ALT Black scientist examines samples using a microscope in the laboratory.